Source comparison
BPC-157 ARA-290 Protocol Neuropathy Research: Clinical Trial Outcomes Comparison
Diabetic neuropathy pilot (2014, Molecular Medicine) ARA-290 monotherapy Type 2 diabetics with confirmed small fiber neuropathy Change in neuropathic pain scores (NPS) at 28 days 42% reduction in NPS vs 12% placebo; improved corneal nerve fiber density ARA-290
This comparison does not assign a generated winner or score.
- Diabetic neuropathy pilot (2014, Molecular Medicine)
- ARA-290 monotherapy
- Type 2 diabetics with confirmed small fiber neuropathy
- Change in neuropathic pain scores (NPS) at 28 days
- 42% reduction in NPS vs 12% placebo; improved corneal nerve fiber density
- ARA-290 controls inflammatory pain but doesn't reverse structural fiber loss. Efficacy peaks early then plateaus
- Chemotherapy-induced neuropathy case series (2018, unpublished)
- BPC-157 monotherapy (500 mcg daily × 12 weeks)
- Post-platinum chemotherapy patients with grade 2–3 neuropathy
- Functional recovery (grip strength, gait velocity) at 12 weeks
- 38% improvement in functional scores; no significant pain reduction
- BPC-157 promotes motor nerve recovery but inadequate for sensory/pain symptoms without anti-inflammatory co-treatment
- Combined protocol case report (2021)
- BPC-157 (250 mcg daily) + ARA-290 (2 mg 3×/week)
- Diabetic patient with failed gabapentin therapy
- Composite symptom reduction (pain, numbness, balance) at 16 weeks
- 58% composite symptom improvement; maintained at 24-week follow-up
- Dual therapy outperformed monotherapy historical controls. Staggered start (ARA-290 first) reported better tolerance
- Rodent sciatic nerve crush model (2020, Brain Research Bulletin)
- BPC-157 vs saline control
- Sciatic nerve transection with surgical repair
- Time to motor function recovery (walking pattern analysis)
- BPC-157 group: 35% faster recovery vs control; histology showed increased myelin thickness
- Animal data. Human translation uncertain, but mechanism validates clinical use for structural nerve repair